Factors influencing the fabrication of albumin-bound drug nanoparticles (ABDns): Part II. Albumin-bound carbamazepine nanoparticles (ABCns)

Abstract

Carbamazepine (CBZ) is a BCS Class II drug with poor solubility profile. In order to improve the physicochemical properties of CBZ, albumin (HSA)-bound CBZ nanoparticles (ABCns) were prepared. Drug-loading studies indicated that monomeric ABCns can be fabricated by self-assembly of anhydrous form III of CBZ and HSA in molar ratios of 1:1 or 2:1 within 0.5 h in phosphate buffer pH 7.4 with particle size in the range of 10–20 nm. Approximately 73–76% of the CBZ was encapsulated within HSA and 20–40% CBZ was released from the ABCns over 8 days. In conclusion, novel ABCns can be fabricated with sustained-release of CBZ for over 8 days which can significantly improve the physicochemical profile of CBZ.

Keywords:

• Carbamazepine
• albumin
• nanoparticles
• fluorescence spectroscopy
• drug release

View correction statement:

Correction to: Erukula and Chatterjee, Factors influencing the fabrication of albumin-bound drug nanoparticles (ABDns): Part II. Albumin-bound carbamazepine nanoparticles (ABCns)

Acknowledgements

The authors would like to thank Vladimir Poltoratsky, PhD for providing A549 cells.

Disclosure statement

The authors report no conflict of interest.